Collaborator News

Advanced Search
  • May 17, 2017

    ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that it will present updated results from its Phase 1, multicenter, dose-escalation study and 20-mg expansion cohort of Ad-RTS-hIL-12 + orally administered veledimex in patients with recurrent or progressive glioblastoma (GBM) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 2-6 in Chicago. Ad-RTS-hIL-12 + veledimex is a novel, viral gene therapy candidate for the controlled expression of interleukin-12 (IL-12), a pro-inflammatory cytokine critical for stimulating anti-cancer immune responses...

  • May 8, 2017

    Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, announced today that the Data Safety Monitoring Board (DSMB) has recommended continuation of the Phase 1/2 clinical trial of FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), following a review of safety data from the first patient treated.  No product-related adverse events were reported...

  • May 2, 2017

    ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that an investigator-initiated Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 1 trial infusing the Company's CD33-specific CAR+ T therapy for relapsed or refractory acute myeloid leukemia (AML) is now active, with the first patient to be enrolled in the study expected to begin treatment in the third quarter of 2017. The CD33-specific CAR+ T cells incorporate a kill switch designed to eliminate the modified T cells under potential adverse safety conditions...

  • Apr 21, 2017

    ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that it will present updated results from its Phase 1, multicenter, dose-escalation study of Ad-RTS-hIL-12 + orally administered veledimex in patients with recurrent or progressive glioblastoma at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 2-6 in Chicago. Ad-RTS-hIL-12 + veledimex is a novel, viral gene therapy candidate for the controlled expression of interleukin-12 (IL-12), a pro-inflammatory cytokine critical for stimulating anti-cancer immune responses...

  • Apr 19, 2017

    Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today announced positive data for SYN-005, the Company's orphan drug program for the prevention and treatment of pertussis (whooping cough). SYN-005 combines two highly synergistic humanized monoclonal antibodies (hu1B7 and hu11E6) to target and potentially inactivate the life-threatening pertussis toxin that causes disease symptoms...


print email